Qurient Co., Ltd. (KOSDAQ:115180)

South Korea flag South Korea · Delayed Price · Currency is KRW
37,300
-2,000 (-5.09%)
At close: Apr 30, 2026
Market Cap1.59T +454.1%
Revenue (ttm)6.98B -23.9%
Net Income-30.05B
EPS-880.00
Shares Out40.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume190,469
Average Volume184,926
Open39,350
Previous Close39,300
Day's Range37,050 - 39,350
52-Week Range9,100 - 62,900
Beta0.57
RSI47.32
Earnings DateMay 12, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 115180
Full Company Profile

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.05 billion, 24.6% more than in 2024.

Financial Statements